MedTrace Logo

Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live

NCT05161845 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1068

Last updated 2023-08-14

No results posted yet for this study

Summary

To evaluate the immunogenicity, lot-to-lot consistency and safety of three consecutive batches of Measles, Mumps and Rubella Combined Vaccine, Live.

Conditions

  • Immunotoxicity
  • Vaccine

Interventions

BIOLOGICAL

Measles, Mumps and Rubella Combined Vaccine, Live

0.5ml of reconstituted vaccine per container. 0.5 ml per single human dose containing not less than 3.0 lg CCID50 of both live measles virus and rubella virus and 4.3 lg CCID50 of live mumps virus.

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Hongxing Pan · Jiangsu Provincial Center for Disease Prevention and Control

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
8 Months
Max Age
12 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2022-04-04
Completion
2022-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05161845 on ClinicalTrials.gov